Caris Life Sciences, Inc. (CAI) stock
CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3093% above fair value
$19.94−1.06 (-5.05%)
Close on Nov 17, 2026Market cap $5.63BP/E –Yield –
Caris Life Sciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Caris Life Sciences's profit margin for the twelve months ending Sep 30, 2026 was 9.2%. For fiscal 2025 it was -8.4%, against -68.4% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -8.4% | +60.0 |
| FY2024 | Dec 31, 2024 | -68.4% | +43.2 |
| FY2023 | Dec 31, 2023 | -111.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 5.5% | −5.7 |
| Q2 FY2026 | Jun 30, 2026 | -0.2% | +39.3 |
| Q1 FY2026 | Mar 31, 2026 | -0.2% | +84.6 |
| Q4 FY2025 | Dec 31, 2025 | 28.0% | +56.4 |
| Q3 FY2025 | Sep 30, 2025 | 11.2% | +77.9 |
| Q2 FY2025 | Jun 30, 2025 | -39.6% | +26.6 |
| Q1 FY2025 | Mar 31, 2025 | -84.8% | – |
| Q4 FY2024 | Dec 31, 2024 | -28.4% | – |
| Q3 FY2024 | Sep 30, 2024 | -66.6% | – |
| Q2 FY2024 | Jun 30, 2024 | -66.2% | – |
See a number that looks wrong?